Article
In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
1 Oct 2020
Abstract excerpt
Background CMP-001 is a novel Toll-like receptor-9 agonist that consists of an unmethylated CpG-A motif-rich G10 oligodeoxynucleotide (ODN) encapsulated in virus-like particles. In situ vaccination of CMP-001 is believed to activate local tumor-associated plasmacytoid dendritic cells (pDCs) leading to type I interferon secretion and tumor antigen presentation to T cells and systemic antitumor T cell responses....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.